Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharmaceutical Giants Fight For Smoking Cessation Market In China

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson recently launched in China its Nicorette chewing gum and patch for people who want to quit smoking. It is the third such global product to enter the country following Novartis' Nicotinell (Nicotinell transdermal nicotine patches)and Pfizer's Champix (varenicline) (PharmAsia News, Dec. 8, 2008) launched respectively in 2007 and 2008. Compared with Nicotinell and Champix, which need prescriptions, OTC Nicorette offers greater accessibility to more people. Industry analysts point out that the huge China market accounts for the three giants' move, but the lack of short-term profit may cause some interested parties to withdraw. Johnson & Johnson agrees with the observation, but stresses its long-term strategy that will see product launches with different flavors. (Click here for more - Chinese Language)

You may also be interested in...



Pfizer Launches Champix In China

Pfizer launched its prescriptive medicine for smokers in China. Champix (varenicline) received approval as a prescription drug to stop smoking from China's State FDA in July. According to the latest epidemiology survey, the number of smokers in China exceeds 350 million, putting it highest worldwide in terms of absolute figure. About one million Chinese die of smoking-related diseases each year. Medical experts say that with the aid of a drug treatment under the supervision of doctors, the success rate of quitting smoking can be doubled. Champix has been in the U.S. market since 2006 and is recommended as a first-line drug. (Click here for more - Chinese language)

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel